Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexproxibutene hemimaleate (CIBA-44328) is a synthetic analgesic compound structurally related to dextropropoxyphene. It is the dextrorotary isomer of 2-(dimethylaminomethyl)-1,2-diphenyl-3-butene-2-ol proprionate in the maleate form. The drug was investigated as an oral analgesic for pain management in conditions such as rheumatoid arthritis and demonstrated intermediate efficacy between paracetamol and stronger agents like aspirin or codeine combinations. Its mechanism of action is presumed to be similar to other diphenylbutylamine derivatives (like dextropropoxyphene), acting primarily as a central nervous system depressant with opioid-like properties[6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexproxibutene hemimaleate.